Stocks Health care KYMR
NASDAQ · Health careKymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. brought in $102.2M of revenue over the twelve months to September 30, 2026, up 133.8% from a year earlier. It posted a net loss of $349.4M. In fiscal 2025 capital spending exceeded operating cash flow by $234.3M. At September 30, 2026 it held $373.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Kymera Therapeutics, Inc.
- Net worth
- Kymera Therapeutics, Inc. has a market value (market cap) of $11.5B at the latest share price, and shareholders' equity of $1.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $39.2M (-16.7% year on year), with a net loss of $311.4M. Over the 12 months to September 30, 2026: revenue $102.2M, net loss $349.4M.
- Cash flow
- In fiscal 2025 operations used $232.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Kymera Therapeutics, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Kymera Therapeutics, Inc. does
Kymera Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker KYMR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $39.2M | -$311.4M | -$3.69 | -$234.3M |
| 2024 | $47.1M | -$223.9M | -$2.98 | -$207.3M |
| 2023 | $78.6M | -$147M | -$2.52 | -$137.3M |
| 2022 | $46.8M | -$154.8M | -$2.87 | -$155.9M |
| 2021 | $72.8M | -$100.2M | -$2.09 | -$130.5M |
| 2020 | $34M | -$45.6M | -$3.15 | $79M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where KYMR ranks in Health care
Latest SEC filings
What Kymera Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026
- October 29, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- September 8, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 466% to $65M versus the same quarter last year; diluted EPS -$0.62 versus -$0.95.
- August 5, 2026
- July 27, 2026
- June 26, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Kymera Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.2M worth of shares in the last 90 days and bought none on the open market. Most of the selling (82%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Mainolfi NelloChief Executive Officer, Director | Exercised options | 30,000 | $62.4K |
| October 1, 2026 | Mainolfi NelloChief Executive Officer, Director | Soldpre-planned (10b5-1) | 3,525 | $392.8K |
| October 1, 2026 | Mainolfi NelloChief Executive Officer, Director | Soldpre-planned (10b5-1) | 5,506 | $619K |
| October 1, 2026 | Mainolfi NelloChief Executive Officer, Director | Soldpre-planned (10b5-1) | 4,876 | $552.2K |
| October 1, 2026 | Mainolfi NelloChief Executive Officer, Director | Soldpre-planned (10b5-1) | 7,601 | $869.8K |
| October 1, 2026 | Mainolfi NelloChief Executive Officer, Director | Soldpre-planned (10b5-1) | 8,230 | $949.7K |
| October 1, 2026 | Mainolfi NelloChief Executive Officer, Director | Soldpre-planned (10b5-1) | 262 | $30.4K |
| September 4, 2026 | Adams BrianChief Legal Officer | Sold | 1,209 | $139.7K |
Who owns KYMR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 14.3% | May 6, 2026 |
| Baker Bros. Advisors LP13D, may seek influence with 3 related filers | 10.9% | December 11, 2025 |
| T. Rowe Price Associates, Inc.13G, passive | 10.7% | September 8, 2026 |
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 9.99% | November 14, 2024 |
| T. Rowe Price Investment Management, Inc.13G, passive | 6.7% | May 15, 2026 |
| BlackRock, Inc.13G, passive | 6.6% | October 27, 2026 |
| Bvf Partners L P13D, may seek influence with 10 related filers | 6.3% | June 26, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 275 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 12,349,256 | +649,306 |
| Baker Bros. Advisors LP | 8,657,242 | 0 |
| Avoro Capital Advisors LLC | 7,474,747 | 0 |
| BlackRock, Inc. | 5,538,210 | +477,334 |
| Bvf Inc | 3,872,052 | -1,630,658 |
| Wellington Management Group Llp | 3,675,028 | -214,659 |
| Vanguard Portfolio Management LLC | 2,992,193 | +118,137 |
| Siren, L.L.C. | 2,935,830 | -251,000 |
| Vanguard Capital Management LLC | 2,932,378 | +52,054 |
| Atlas Venture Life Science Advisors, LLC | 2,847,541 | -1,730,467 |
| State Street Corp | 2,737,226 | +347,459 |
| Geode Capital Management, LLC | 1,816,331 | +170,981 |
| Capital Research Global Investors | 1,388,881 | -284,394 |
| Goldman Sachs Group Inc | 1,187,333 | +298,924 |
| UBS Group AG | 1,007,777 | -16,075 |
| Driehaus Capital Management LLC | 919,233 | -124,350 |
| Merck & Co., Inc. | 772,165 | 0 |
| Norges Bank | 757,246 | new |
| Federated Hermes, Inc. | 749,398 | +212,718 |
| Dimensional Fund Advisors LP | 745,152 | +152,273 |
Insiders
11 insiders reported holding 9,946,718 shares in total, about $1.38B at the last price.
| Holder | Shares |
|---|---|
| Baker Bros. Advisors LPDirector, 10% owner | 7,955,9167,955,916 held indirectly |
| Mainolfi NelloChief Executive Officer, Director | 666,568 |
| Booth BruceDirector | 462,856462,856 held indirectly |
| Bvf Partners L P/IlDirector | 318,91078,787 held indirectly |
| Jacobs Bruce N.Chief Financial Officer | 244,883 |
| Gollob JaredChief Medical Officer | 117,134 |
| Adams BrianChief Legal Officer | 50,254 |
| Goodman NoahChief Business Officer | 47,179 |
| Chadwick Jeremy GChief Operating Officer | 44,018 |
| Rooney TerenceChief Medical Officer | 38,000 |
Questions about KYMR
What does Kymera Therapeutics, Inc. do?
Kymera Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as KYMR. Its shares trade on NASDAQ under the ticker KYMR.
What is Kymera Therapeutics, Inc.'s net worth?
Kymera Therapeutics, Inc. has a market value (market cap) of $11.5B at the latest share price, and shareholders' equity of $1.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Kymera Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $349.4M on revenue of $102.2M.
How much revenue does Kymera Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Kymera Therapeutics, Inc. reported revenue of $102.2M. That is 133.8% more than a year earlier.
When did Kymera Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026.
When is Kymera Therapeutics, Inc.'s next earnings report?
Kymera Therapeutics, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KYMR with
Follow KYMR
Get an email when Kymera Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kymera Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.